Table 1.

Patient characteristics (n = 14)

CharacteristicsPatients, n
Median age (range), y 59 (44-84) 
Male sex, n (%) 11 (79) 
ECOGstatus, n (%)  
 0 2 (14) 
 1 11 (79) 
 2 1 (7) 
Primary histologic diagnosis  
 Enteropathy-associated T-cell lymphoma, type II 
 γ-δ hepatosplenic T-cell lymphoma 
 HTLV-1 associated adult T-cell leukemia/lymphoma 
 Peripheral T-cell lymphoma, not otherwise specified 
 Alk-negative anaplastic large cell lymphoma 
 MF 
 MF transformed to large cell lymphoma 
 MF/SS 
 Cutaneous γ-δ T-cell lymphoma 
Disease stage at study entry, n (%)  
 PTCL (n = 7)  
  Stage IV 7 (100) 
 CTCL (n = 7)  
  MF, stage IB 2 (14) 
  MF, stage IVA1 2 (14) 
  MF transformed to large cell lymphoma, stage IV 2 (14) 
  Cutaneous γ-δ T-cell lymphoma, stage IV 1 (7) 
Refractory to most recent therapy, n (%) 14 (100) 
Median time from diagnosis to study entry (range), y 4.4 (0.4-14.8) 
Median prior lines of therapy, n (range) 4 (1-11) 
For MF patients (n = 6), prior systemic treatment, n (%) 
 Histone deacetylase inhibitor 5 (83) 
 Oral retinoid therapy 6 (100) 
 Oral methotrexate 4 (67) 
 Interferon 3 (50) 
 Chemotherapy 5 (83) 
 Total skin electron beam therapy 4 (67) 
 Denileukin diftitox 1 (17) 
 Alemtuzumab 1 (17) 
CharacteristicsPatients, n
Median age (range), y 59 (44-84) 
Male sex, n (%) 11 (79) 
ECOGstatus, n (%)  
 0 2 (14) 
 1 11 (79) 
 2 1 (7) 
Primary histologic diagnosis  
 Enteropathy-associated T-cell lymphoma, type II 
 γ-δ hepatosplenic T-cell lymphoma 
 HTLV-1 associated adult T-cell leukemia/lymphoma 
 Peripheral T-cell lymphoma, not otherwise specified 
 Alk-negative anaplastic large cell lymphoma 
 MF 
 MF transformed to large cell lymphoma 
 MF/SS 
 Cutaneous γ-δ T-cell lymphoma 
Disease stage at study entry, n (%)  
 PTCL (n = 7)  
  Stage IV 7 (100) 
 CTCL (n = 7)  
  MF, stage IB 2 (14) 
  MF, stage IVA1 2 (14) 
  MF transformed to large cell lymphoma, stage IV 2 (14) 
  Cutaneous γ-δ T-cell lymphoma, stage IV 1 (7) 
Refractory to most recent therapy, n (%) 14 (100) 
Median time from diagnosis to study entry (range), y 4.4 (0.4-14.8) 
Median prior lines of therapy, n (range) 4 (1-11) 
For MF patients (n = 6), prior systemic treatment, n (%) 
 Histone deacetylase inhibitor 5 (83) 
 Oral retinoid therapy 6 (100) 
 Oral methotrexate 4 (67) 
 Interferon 3 (50) 
 Chemotherapy 5 (83) 
 Total skin electron beam therapy 4 (67) 
 Denileukin diftitox 1 (17) 
 Alemtuzumab 1 (17) 

ECOG, Eastern Cooperative Oncology Group; MF, mycosis fungoides; SS, Sezary syndrome.

Close Modal

or Create an Account

Close Modal
Close Modal